secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001682852-24-000010
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q4 2023 revenue $2.8B, EPS $0.55; FY net loss $4.7B from $3.7B non-cash charges
--------------------------------------------------------------------------------

- Q4 revenue $2.8B (-43% YoY); GAAP net income $217M, diluted EPS $0.55.
- FY2023 revenue $6.8B; GAAP net loss $4.7B, diluted EPS ($12.33) from $3.7B non-cash charges (resizing, valuation allowance).
- Reaffirms 2024 product sales ~$4B; expects RSV vaccine (mRNA-1345) regulatory approvals beginning H1 2024 (PDUFA May 12).
- FY2023 COVID vaccine sales $6.7B; U.S. retail market share 48% (vs 37% in 2022).
- 2024 guidance: cost of sales ~35% of product sales; R&D ~$4.5B; SG&A ~$1.3B; year-end cash ~$9B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000010/0001682852-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000010/mrna-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001682852-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer